The Lancet Oncology: March 26, 2008

from Listen to The Lancet Oncology · host The Lancet

Editor David Collingridge discusses highlights from the April issue including: encouraging results from the START trials suggest fewer fractions of radiotherapy could revolutionise treatment of early stage breast cancer; how a phase II study investigating yttrium-90 labelled ibritumomab could have an important future role in the treatment of follicular non-Hodgkin lymphoma, and finally the pressing need for increased recruitment of adolescents and young adults in to cancer trials.

Episode metadata supplied by the publisher feed · Published Mar 26, 2008

Embed this episode

Attribution link and audio player

NOW PLAYING

The Lancet Oncology: March 26, 2008

0:00 12:25

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Listen to The Lancet Oncology?

This episode is 12 minutes long.

When was this Listen to The Lancet Oncology episode published?

This episode was published on March 26, 2008.

Can I download this Listen to The Lancet Oncology episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!